Health Condition 1: H401- Open-angle glaucoma
Conditions
Interventions
Intervention1: Netarsudil: 0.02% ophthalmic solution once daily for 6 months
Control Intervention1: Latanoprost: 0.005% ophthalmic solution once daily for 6 months
Sponsors
Dr Rinky Thakur
Eligibility
Inclusion criteria
Inclusion criteria: Male or female patients aged >18years Patients with newly-diagnosed Primary open angle glaucoma by the treating physician with mean IOP >21 mmHg and Patients with best corrected visual acuity of >6/60 in both eyes Willingness to follow study requirements including written informed consent
Exclusion criteria
Exclusion criteria: Patients already on ocular hypotensive drugs Patients with mean IOP less than or equal to 21 mmHg Patients with mean IOP greater than or equal to 30 mmHg in either eye Patients with ocular infection or inflammation in either eye Patients with any active ocular disease in either eye other than Primary open angle glaucoma or with systemic disease that could interfere with study results History of ocular trauma, angle closure or narrow iridocorneal angles (including previous peripheral iridotomy) previous glaucoma incisional surgery or laser surgery or refractive surgery Central corneal thickness >600 micrometer Patients with any abnormality preventing reliable applanation tonometry of either eye Known hypersensitivity to or contraindications to study drugs Women of childbearing potential who are pregnant, nursing or planning a pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To compare the mean change in Intra Ocular Pressure over 6 months of treatment in newly diagnosed POAG patients treated with Netarsudil 0.02% Once daily & Latanoprost 0.005% Once daily ophthalmic solutionsTimepoint: The present study will be of one year duration with 6 month follow up of every patient Each study patient will be followed up at 2 weeks then 4 weeks then 4 months & 6 months | — |
Secondary
| Measure | Time frame |
|---|---|
| 1st To compare the change in visual field of newly diagnosed Primary open angle glaucoma patients treated with Netarsudil 0.02% OD & Latanoprost 0.005% OD ophthalmic solutions 2nd To compare the safety of Netarsudil 0.02% OD and Latanoprost 0.005% OD in such patients by comparing the adverse effects reported voluntarily by the patients and those enquired or observed Timepoint: The change in visual field will be assessed at 6 months for every patient The patients will be assessed for & enquired regarding adverse effects at 2 weeks then 4 weeks then 4 months and at 6 months | — |
Countries
India
Contacts
Public ContactDr Rinky Thakur
Indira Gandhi Institute of Medical Sciences
Outcome results
None listed